Praluent

Chemical Namealirocumab
Dosage FormInjection (subcutaneous; 75 mg/mL, 150 mg/mL)
Drug ClassInhibitors
SystemCardiovascular
CompanySanofi-Aventis
Approval Year2015

Indication

  • To reduce the risk of myocardial infarction, stroke, and unstable angina requiring hospitalization in adults with established cardiovascular disease.
  • As adjunct to diet, alone or in combination with other lipid-lowering therapies (e.g., statins, ezetimibe), for the treatment of adults with primary hyperlipidemia (including heterozygous familial hypercholesterolemia) to reduce low-density lipoprotein cholesterol LDL-C.
Last updated on 10/15/2020

More on this drug: Clinical Trials

Have we missed a study, or would you like to comment on a study?

Document TitleYearSource
Praluent (alirocumab) Prescribing Information 2020Sanofi-aventis U.S. LLC, Bridgewater, NJ